Sirna Therapeutics and GlaxoSmithKline (GSK) have initiated programs in asthma and respiratory syncytial virus (RSV) as part of an exclusive, multi-year collaboration in respiratory diseases. The companies also plan to pursue RNAi-based therapeutics against chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Sirna will provide GSK with optimized and formulated siRNAs against targets for these diseases and GSK will assume all responsibility for the further preclinical and clinical...